Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
2021 IEEE International Geoscience and Remote Sensing Symposium, IGARSS 2021 ; : 1563-1566, 2021.
Article in English | Scopus | ID: covidwho-1861123

ABSTRACT

In order to control the spread of the pandemic of Corona-Virus Disease 2019 (COVID-19), lockdowns of various durations and intensities have been established in many countries over the world all through the year 2020. The trilateral dashboard jointly implemented by NASA, JAXA and ESA aims at exploiting remote-sensing data to evaluate the impact of these restrictions, and subsequent recovery phases on many different environmental, agriculture and economic indicators. More specifically, this paper presents the indicators implemented to monitor the impact of COVID-19 restrictions on Water Quality, together with preliminary analysis results over a few Areas of Interest. © 2021 IEEE.

2.
Hematology, Transfusion and Cell Therapy ; 43:S544, 2021.
Article in English | EMBASE | ID: covidwho-1859765

ABSTRACT

Introdução: A doença coronavírus 2019 (COVID-19) é uma infecção respiratória causada pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2), com uma gravidade dos sintomas que varia de uma doença leve a uma pneumonia viral grave que leva à síndrome do desconforto respiratório agudo potencialmente fatal. Os sintomas mais comuns são: febre, tosse, dispneia, mialgia e cansaço. A taxa de letalidade é baixa nas faixas etárias mais baixas e aumenta após os 60 anos de idade. Alguns estudos apontam que o vírus SARS-CoV-2 pode sobreviver em superfícies por vários dias, dependendo do tipo, temperatura ou umidade do ambiente. Os serviços de saúde, enquanto serviços essenciais, devem ter o cuidado excepcional para evitar a contaminação dos equipamentos, pacientes e profissionais. Em tempos de pandemia, tomar medidas que garantam a prevenção, a minimização ou a eliminação de riscos à saúde é fundamental. Por décadas, as normas relativas à biossegurança foram negligenciadas, mas, com o advento da COVID-19, medidas básicas estão sendo reconsideradas, principalmente no que diz respeito aos cuidados necessários para a minimização dos riscos biológicos ao profissional da saúde. A Agência Nacional de Vigilância Sanitária (ANVISA) define a Biossegurança como um conjunto de medidas técnicas que são de suma importância durante a manipulação de agentes e materiais biológicos. Inúmeras são as ações de controle que estão sendo reforçadas a partir das experiências de outros países e da experiência de saúde acumulada em tratamento de outras doenças respiratórias que apresentam meios de transmissão semelhante ao da COVID-19. Objetivo: Descrever as medidas de biossegurança utilizadas para prevenção da Covid 19;Contribuir com a construção de conhecimento sobre a Covid 19. Metodologia: Assim, baseados nestas experiências, faremos um relato de experiência das ações que foram tomadas para mitigar o efeito da COVID-19 em profissionais de saúde de um Hemocentro de Fortaleza. As medidas de enfretamento ao Covid 19 foram correlacionadas em cinco tópicos: Biossegurança e Trabalhador, Comunicação, Portas de Entrada, Doadores/ Pacientes e Insumos e EPIs. Conclusão: Os estudos e autoridades sanitárias de saúde mundial, nacional, estadual e municipal ainda não indicam um período para finalização da pandemia provocada pelo novo coronavírus. A importância de elaborar um Plano de Biossegurança veio garantir a segurança dos profissionais bem como pacientes/ doadores que precisam de atendimento no serviço. O trabalho de educação em saúde deve ser permanente visto que a doença vem sendo estudada e que pouco se sabe. As novas evidências apontam para cepas variantes fazendo com que as medidas de precauções não cessem e que os cuidados sejam redobrados, contínuos e regados de conscientização acerca das medidas sociais de minimização de contaminação.

4.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation ; 41(4):S222-S223, 2022.
Article in English | EuropePMC | ID: covidwho-1781799

ABSTRACT

Introduction Heart tansplant (HT) recipients constitute a population at risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Efficay and safety of SARS-CoV-2 vaccine in this population is still yet to be established. It has been described, immune thrombotic thrombocytopenia, myocarditis and Guillain-Barre syndrome in individuals who received the ChAdOx1 SARS-CoV-2 vaccine. There are very few cases of acute rejection after SARS-CoV-2 vaccination post HT patients. We will describe a several outcome of heart function vaccine-induced. Case Report A 46-year-old heart transplanted male since 2015, started with persistent cough 15 days after a dose of adenoviral vector-based vaccine against SARS-CoV-2. As he had increased troponin and new left ventricular dysfunction, he underwent an endomyocardial biopsy, collected an panel reactive antibodies (PRA) and started pulse dose metylprednisolone. He developed an ischemic electrocardiographic alteration with a ST elevation and the coronary angiography found a thrombosis in the anterior descending coronary artery with no success with percutaneous treatment. Endomyocardial biopsy found no acute rejection, and PRA showed de novo donor specific antibodies (DSA). Despite treatment for antibodie-mediated rejection with plasmapheresis, human immunoglobulin and rituximab, he had a cardiogenic shock, refractory to inotropic support and intra-aortic balloon pump, requiring peripheral VA ECMO. Regardless of initial hemodynamic response and partial recovery of biventricular function, patient could not stand weaning from ECMO and inotropes. After rejection therapy, PRA showed no antibodies and patient was included in HT list and had a retransplant after 16 days without complications. Summary To the best of our knowledge, this is the firts report of antibodie-mediated rejection in heart-transplant patient with thrombotic complication after ChAdOx1 SARS-CoV-2 vaccine. Although vaccination remains the main approach of preventing SARS-CoV-2 infeccion, transplant recipients were not included in clinical trials, so its safety remains unknown in this population. More studies are needed in order to increase knowledge about vaccine outcomes in these individuals.

5.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation ; 41(4):S328-S328, 2022.
Article in English | EuropePMC | ID: covidwho-1781798

ABSTRACT

Purpose A recent UNOS analysis comparing COVID-19 to pre-COVID-19 era found an increased waitlist inactivation, decreased waitlist addition, and decreased in numbers of heart transplant (HT). In Brazil, a pronounced negative effect on transplant was anticipated but has not been measured so far. Our objective was to evaluate the impact of COVID-19 pandemic on heart donation and HT. Methods We performed a descriptive analysis of data related to patients registered in HT waitlist and numbers of HT performed from March 2018 to August 2019 (pre-COVID era) and March 2020 to August 2021 (COVID era), by reviewing medical records and data from State Transplant System. Results A total of 221 patients were included in HT waitlist from 2018 to 2021. Approximately the same number of patients were listed in pre-COVID and COVID era (111 vs 110, respectively). Mean age of patients were 48.7 in the pre COVID and 48.9 years in the COVID era (p=0.91). The majority were listed as top priority criteria, 94 (85.5%) in COVID vs 100 (90.1%) in pre-COVID era, p=0.293, mostly due to mechanical circulatory assist devices ECMO and Centrimag (10.9% vs 18%), and intra-aortic balloon pump (41.8 % vs 39.6%) respectively, p=0.496. There was no difference in the survival of patients in waitlist (p = 0.226). Regarding number of HT, we observed highest absolute number of surgeries in the pre-COVID era (78 vs 66), with no statistical significance (p=0.109). There was no difference between the deaths after HT, 17 (15.3%) in pre-COVID and 9 (8.2%) in COVID era, p=0.249. During the peak of number of COVID-19 cases in Brazil (may-july 2020 and february-april 2021) we observe a reduction in overall heart transplant procedures an inclusion in waitlist (figure). Conclusion To the best of our knowledge, this is the first report of the impact of COVID - 19 on solid organ donation and HT. There were no differences between number of patients included in HT waitlist and outcomes after HT before and during COVID. However, there was a decrease in number of HT and inclusion in HT waitlist during the peak of COVID-19.

6.
2021 IEEE International Geoscience and Remote Sensing Symposium, IGARSS 2021 ; 2021-July:1380-1383, 2021.
Article in English | Scopus | ID: covidwho-1746061

ABSTRACT

PRISMA, in orbit since March the 22nd 2019, opened the user access in spring 2020. After one year, many hundreds of users have gained the capability to program new acquisitions or download image products from the online archive containing more than 67k datasets, under a quasi-open & free data policy and licensing scheme. During this time frame and despite the COVID-19 related difficulties, PRISMA performed normal operations delivering not only nominal verified quality data to users but establishing collaborations with other space agencies, in order to enable and support synergies with other hyperspectral missions. This paper describes the mission and the results achieved in this first period of full operational usage. © 2021 IEEE.

7.
2021 IEEE International Geoscience and Remote Sensing Symposium, IGARSS 2021 ; 2021-July:7516-7519, 2021.
Article in English | Scopus | ID: covidwho-1746057

ABSTRACT

COVID-19 lockdown measures brought to a drastic reduction of anthropic impacts on the environment, including the marine-coastal system. EO data have the potential to monitor and diagnose the subsequent effects of the lockdown in terms of water quality. The ESA-RACE project SOON aims to link complex patterns that may arise from the environmental changes due to COVID-19 lockdown by using EO data, also seeking to assess connectivity between inland and marine system. Within this frame, here we present a holistic, satellite-based analysis of the spatial-temporal variability of environmental parameters in the North Adriatic Sea (NAS;Mediterranean basin), exploiting the synergy of OC and SST products from different sensors, as well as in situ hydrologic data. Our analysis indicates a favorable interplay of environmental variability and reduction of anthropogenic activity that results in negative anomalies of Chlorophyll-a and Total Suspended Matter with respect to the climatologic values. © 2021 IEEE

8.
Annals of Oncology ; 32:S1155-S1156, 2021.
Article in English | EMBASE | ID: covidwho-1432914

ABSTRACT

Background: The onset of COVID-19 pandemic forced lockdown and halted breast cancer screening programs. We aimed to investigate the impact of COVID-19 on the new diagnosis and staging of breast cancer. Methods: In this cohort study, we included all patient with new diagnosis of breast cancer who were admitted to our Hospital (Hospital Pedro Hispano, Matosinhos, Portugal), between March 2019 and March 2021. We collected data on baseline clinical conditions such as age, stage at diagnosis and treatment. We created two different groups were created: 1st group- before COVID-19 pandemia (March 1, 2019 to March 16, 2020);2nd group - COVID-19 pandemia (March 17, 2020 to March 31, 2021). A comparative assessment between groups was carried out. Results: Were included 483 patients;n=289 in the 1st group and n= 194 in the 2nd group. The median age was 60 years old in the 1st group and 59 years old in the 2nd group. In the 1st group, 13% patients were diagnosis with ductal in situ carcinoma (DCIS), 51% in stage I, 24% in stage II, 9.5% in stage III and 3% in stage IV. In 2nd group, 9% had DCIS, 30% were in stage I, 40% in stage II, 11% in stage III and 10% in stage IV. Stage at diagnosis was significantly higher in the 2nd group (p< 0.001) This situation was mainly due to tumour size (T). In the 1st group, most patients (n=91;38%) had tumour size between 10 e 20mm (T1c in TNM classification). One the other hand, 40% (n=78) of patients included in the 2nd group had tumour size between 20 e 50mm (T2), with significant differences between them (p=0.004). No difference was found between groups in nodular involvement (p=0.189), with the majority of patients (∼50% in both groups) presenting without nodular involvement (N0 in TMN classification). 10% of patients in 2nd group and 3% in 1st group had metastatic disease at diagnosis, with differences between them (p=0.006). 49% (n=119) of patients in 1st group and 52% (n=100) in the 2nd group were treated with chemotherapy, without differences between those groups. Conclusions: Our results show that during one year after COVID-19 pandemia the incidence of breast cancer decreased, and patients were diagnosis in more advanced stages. This situation could have been related to patient referral to non COVID-19 Hospitals or correspond to a true sub-diagnosis. Legal entity responsible for the study: M. Vilaça. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

10.
Humanidades & Inovacao ; 8(40):252-268, 2021.
Article in Portuguese | Web of Science | ID: covidwho-1348923

ABSTRACT

This paper presents a research developed from the training course in Dialogic Learning carried out during the period of social distance and in a remote way, which sought to promote the training of several educational agents. The research was carried out by means of an electronic form filled out by the course participants after the end of the activity so that we could understand how and if the Dialogic Pedagogical Training impacted aspects of life during the COVID-19 pandemic. As a result, we highlight the centrality in the instrumental dimension of the knowledge covered throughout the course, the possibility of virtual dialogue and the organization of studies as transforming elements for coping with social distance. We hope with this article to contribute to the field of teacher education through Dialogic Learning as a powerful tool for a liberating education based on scientific evidence in relation to the most relevant educational theories and research in the current scenario.

11.
Journal of Heart and Lung Transplantation ; 40(4):S471-S471, 2021.
Article in English | Web of Science | ID: covidwho-1187383
14.
Annals of Oncology ; 31:S1028, 2020.
Article in English | EMBASE | ID: covidwho-806289

ABSTRACT

Background: On March 11, 2020, COVID-19 was declared a global pandemic. Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this infection may remain asymptomatic. The European Society of Medical Oncology and the Portuguese Health Authority recommended both a symptomatic survey and laboratory testing in all cancer patients (pts) undergoing immunosuppressive treatment (IT). The impact of this measure is still unknown. We report our experience in a Portuguese center. Methods: Since March 2020, a symptomatic survey has been performed at our institution before each hospital visit. From April 6 through May 8, 2020, reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 testing was added on cancer pts before undergoing IT. The impact of this intervention was evaluated comparing the hospitalization rate of cancer pts due to COVID-19, before and after the introduction of RT-PCR testing. Retrospective analysis of clinical data was performed. Results: 444 tests were carried out on 244 pts and laboratory SARS-CoV-2 infection was confirmed in 11 (5%);5 were male, with a median age of 65 years [34-76]. Breast and colorectal cancer were prevalent;2 pts had lung cancer;6 advanced disease. Ongoing IT in these pts was temporarily suspended: 9 pts under chemotherapy, 1 atezolizumab and 1 rituximab. Only 1 patient was symptomatic (9%) and previously hospitalized. No admission due to COVID-19 was registered in this group. Since March 7, 179 pts were admitted due to COVID-19 at our center: 12 were active cancer pts (6.7%) of which 4 were under IT. 6 of the oncological pts passed away, all of them had advanced diseases, 1 was under IT. Of the dead pts, lung and breast tumors were prevalent. Among all COVID-19 hospitalizations, the prevalence of pts under IT was similar before and after the implementation of the RT-PCR testing (2.2% vs. 2.4%). Conclusions: We found a significant percentage of active cancer pts diagnosed with asymptomatic COVID-19. Due to the small sample size of COVID-19 pts under IT, it is difficult to evaluate the impact of RT-PCR testing. However, on a long-term analysis, this intervention may reduce the risk of severe complications related to COVID-19 in cancer pts. Health education and dynamic organization are also important measures. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

SELECTION OF CITATIONS
SEARCH DETAIL